PIPA5114471

CD272 (BTLA) Polyclonal Antibody, Invitrogen™

Manufacturer: Thermo Scientific

Select a Size

Pack Size SKU Availability Price
Each of 1 PIPA5114471-Each-of-1 In Stock ₹ 46,502.50

PIPA5114471 - Each of 1

₹ 46,502.50

In Stock

Quantity

1

Base Price: ₹ 46,502.50

GST (18%): ₹ 8,370.45

Total Price: ₹ 54,872.95

Antigen

CD272 (BTLA)

Classification

Polyclonal

Conjugate

Unconjugated

Gene

BTLA

Gene Alias

A630002H24; B and T lymphocyte associated; B and T lymphocyte associated protein; B and T lymphocyte attenuator; B- and T-lymphocyte attenuator; B- and T-lymphocyte-associated protein; BTLA; BTLA_HUMAN; BTLA1; CD272; CD272 antigen; FLJ16065; MGC129743

Host Species

Rabbit

Purification Method

Antigen affinity chromatography

Regulatory Status

RUO

Gene ID (Entrez)

151888

Content And Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Form

Liquid

Applications

Immunohistochemistry (Paraffin), Western Blot

Concentration

1 mg/mL

Formulation

PBS with 0.02% sodium azide

Gene Accession No.

Q7Z6A9

Gene Symbols

BTLA

Immunogen

BTLA antibody was raised against a 17 amino acid peptide near the center of human BTLA. The immunogen is located within amino acids 170 - 220 of BTLA.

Quantity

100 μg

Primary or Secondary

Primary

Target Species

Human

Product Type

Antibody

Isotype

IgG

Related Products

Img

Thermo Scientific

PIPA5114467

--

Img

Thermo Scientific

PIPA5114490

--

Img

Thermo Scientific

PIPA5114524

--

Img

Thermo Scientific

PIPA5114526

--

Img

Thermo Scientific

PIPA5114500

--

Img

Thermo Scientific

PIPA5114452

--

Img

Thermo Scientific

PIPA5114521

--

Img

Thermo Scientific

PIPA5114487

--

Description

  • Positive controls that may be used include: Jurkat Cell Lysate, Human Small Intestine Tissue Slide BTLA or B and T-lymphocyte attenuator is a member of the co-inhibitory receptors of the CD28 superfamily
  • BTLA is a lymphocyte inhibitory receptor which inhibits lymphocytes during immunes responses
  • BTLA is constitutively expressed on most CD4+ and CD8+ T cells and its expression progressively decreases upon T cell activation
  • It remains expressed on Th1 cells, but not Th2 cells
  • BTLA is a unique co-receptor that interacts with the tumor necrosis factor receptor superfamily member herpesvirus entry mediator (HVEM)
  • This interation is an important pathway regulating lymphocyte activation and/or homeostasis in the immune response.